Community Hospitals
e-Newsletter
Intelligence Unit Special Reports Special Events Subscribe Sponsored Departments Follow Us

Twitter Facebook LinkedIn RSS

Genetic research advance yields new lupus treatment



The Food and Drug Administration approved the first new drug for lupus in more than 50 years, a major milestone in the effort to mine data from the human genome to discover and develop new medicines. The drug, called Benlysta, will be co-marketed by Human Genome Sciences Inc., a Rockville, MD, company that has been on a roller-coaster journey for nearly two decades to develop the medicine, and GlaxoSmithKline PLC, whose investment in the biotech company was one of the first big bets a major pharmaceutical company placed on genomic research. Analysts expect the drug to reach blockbuster status, with sales eventually topping $1 billion a year.
Name:
E-mail:
Website:  
Please enter your comment below:
Please enter the text below: